Resources
- BNET Author Biography
- Trista Morrison is a staff writer at BioWorld Today, a daily newspaper that
- more about Trista Morrison »
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Despite Omeros Flop, Trius and Other Biotech IPO Hopefuls Might Fare Better
- Trius Therapeutics added its name to the initial public offering queue on Friday, apparently undeterred by the abysmal performance of Omeros Corp., the first true biotech to go public in the current IPO window. by Trista Morrison
- Blog posts 2009-11-08
- UPDATED: Immunomedics Ignored, HGS Adored as Annual Rheumatology Confab Kicks Off
- The American College of Rheumatology's annual confab kicks off this weekend, and one item not on the menu is detailed Phase IIb data for Immunomedics and partner UCB's lupus drug epratuzumab. Meanwhile Human Genome Sciences’ lupus drug Benlysta looks to be the belle of the ball. by Trista Morrison
- Blog posts 2009-10-15
- The Scoop on MannKind's Afresa Partnership Delay
- MannKind’s president and chief operating officer, Hakan Edstrom, explains why the company's partnership for inhaled insulin product Afresa has been delayed. by Trista Morrison
- Blog posts 2009-10-11
- Are You Sure You Want Off-Label Drug Promotion Protected Under Freedom of Speech?
- On what planet is Allergan's lawsuit, which claims the FDA's off-label drug promotion ban violates the First Amendment right to free speech, a good idea? It doesn't appear to serve the greater good for the public or even for the drug industry. by Trista Morrison
- Blog posts 2009-10-07
- Talecris IPO Gives Cerberus Much-Needed Happy Ending
- The $950 million initial public offering priced by Talecris Biotherapeutics last week was good for a lot of people -- perhaps none more than private equity firm Cerberus Partners, which was desperately in need of a happy ending. by Trista Morrison
- Blog posts 2009-10-05
- Chelsea and Catalyst Roll the Dice on Re-Analyses, Investors Take the Bet
- Chelsea Therapeutics and Catalyst Pharmaceutical Partners both enjoyed nice stock bumps last week thanks to re-analyses of failed clinical trials, even though such analyses often prove to be nothing but trouble for biotechs. by Trista Morrison
- Blog posts 2009-10-04
- Dirty Politicians Pressured the FDA to Approve Something Unsafe? Say It Ain't So.
- The FDA is investigating one of its past approval decisions, publicly questioning for the first time whether or not political pressure unduly influenced an outcome. Note this is the first time they're questioning it -- not necessarily the first time it has happened. by Trista Morrison
- Blog posts 2009-09-30
- War Stories II: Sunesis Hunkers Down and Gets Creative to Stay Alive
- In another war story from the BioPharm America conference front lines, Sunesis CEO Dan Swisher tells how his company, on the brink of running out of cash in January, hunkered down and got creative with its investors to close a PIPE. by Trista Morrison
- Blog posts 2009-09-28
- War Stories I: Turnaround Takes MDRNA from Two Weeks of Cash to Seven Deals
- At the recent BioPharm America conference in San Francisco, biotech CEOs and investors swapped war stories - including this one about how MDRNA made it back from the brink. by Trista Morrison
- Blog posts 2009-09-27
- Who's Afraid of Big, Bad Cardiovascular? Apparently Not Biotech...
- Cardiovascular disease brings to mind huge, expensive clinical trials and huge, expensive primary care sales forces…but not necessarily huge, expensive drug prices. With the basics of cholesterol management met, some big pharmas are turning away from the field, but enterprising biotechs are stepping in. by Trista Morrison
- Blog posts 2009-09-24
- Playing Devil's Advocate on the Talecris IPO: A Banker Provides the Contrarian View
- Earlier this week, I argued that you’d have to be a fool to buy into the Talecris Biotherapeutics initial public offering. Now a banker presents the other side of the story. by Trista Morrison
- Blog posts 2009-09-23
- Biotech Fundraising Options for Those With No Options
- Yes, the financing climate appears to be thawing, and for those with good data, it’s been positively hot. But there are still plenty of biotechs being forced to get creative with their fundraising efforts. by Trista Morrison
- Blog posts 2009-09-21
- Former CellCyte Execs Sued by SEC for Role in Pump and Dump Stock Scheme
- In case you were wondering why counsel always cuts the hype out of your press releases…CellCyte Genetics and its former top execs got slapped with an SEC lawsuit for their role in a hype-driven pump-and-dump stock scheme. by Trista Morrison
- Blog posts 2009-09-10
- Immunomedics: P-Values? Phooey! These Lupus Data Look Great, Trust Us!
- Last week’s press release from Immunomedics and partner UCB concerning lupus drug epratuzumab’s success in a Phase IIb trial seemed to be missing something -- statistical significance. by Trista Morrison
- Blog posts 2009-08-31
- WHO Report: Underfunded Neglected Diseases Need A Marketing Makeover
- A research paper in this month’s Bulletin of the World Health Organization suggests that, when it comes to disease funding, perception is reality. Some diseases get more than their fair share of government and nonprofit funding, and the researchers say it all comes down to positioning. by Trista Morrison
- Blog posts 2009-08-30
- Well Isn't That Special: Overall Survival Still Oncology Gold Standard
- There’s a world of difference between thinking your kid is the smartest in class and selling the principal on the idea, as cancer drug makers are learning when trying to sell the FDA on progression-free survival as a primary endpoint. by Trista Morrison
- Blog posts 2009-10-12
- Depomed Unfairly Slammed for Serada Phase III Results
- Under-the-radar drug delivery firm Depomed doesn't deserve the heat it's been taking on mixed results from two Phase III trials of hot flash drug Serada. by Trista Morrison
- Blog posts 2009-10-13
- Has Genta's Energizer Bunny of Cancer Drugs Finally Run Out of Juice?
- The most surprising thing about last week's Phase III failure of beleaguered cancer drug Genasense was that Genta's stock plummeted. Seriously, who didn't see this one coming? by Trista Morrison
- Blog posts 2009-11-04
- Sloppy End of Year FDA Filings Have Lower Approval Odds
- In the fourth quarter, the FDA receives more new drug applications -- and approves less of them -- than at any other time of year. The reason? Companies rushing to hit self-imposed year-end deadlines. by Trista Morrison
- Blog posts 2009-11-01
- Hepatitis C Drugs Kill the Virus...and Your Sex Drive
- As the American Association for the Study of Liver Diseases kicks off its annual confab this week, all eyes will be on efforts to revolutionize the standard of care for hepatitis C...especially now that new data show the standard has unfortunate sexual side effects. by Trista Morrison
- Blog posts 2009-10-27
- << Previous
- page 1 of 4
- Next >>
Refining Tags
- Biotechnology (26 results)
- Finance (15 results)
- Government (11 results)
- Investment (11 results)
- Federal Government (9 results)
- IPO (6 results)
- Financial Planning (6 results)
- Financial Services (6 results)
- Financial Accounting (5 results)
- Marketing (4 results)
- Human Resources (4 results)
- Healthcare (4 results)
- FDA (3 results)
- Investor (3 results)
- Pharmaceutical Company (3 results)
- Amgen Inc. (3 results)
- Management (3 results)
- Genentech Inc. (3 results)
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
